Strensiq Solution
Product Images NDC 25682-019

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Strensiq (NDC 25682-019). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alexion Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Strensiq 01)

FDA Label Image

Figure A (Strensiq 02)

FDA Label Image

Figure (Strensiq 03)

FDA Label Image

Figure (Strensiq 04)

FDA Label Image

Figure (Strensiq 05)

FDA Label Image

Figure (Strensiq 06)

FDA Label Image

Figure (Strensiq 07)

FDA Label Image

Figure (Strensiq 08)

FDA Label Image

Figure (Strensiq 09)

FDA Label Image

Figure (Strensiq 10)

FDA Label Image

Figure (Strensiq 11)

FDA Label Image

Figure (Strensiq 12)

FDA Label Image

Figure (Strensiq 13)

FDA Label Image

Figure (Strensiq 14)

This document appears to be a mix of random characters and some recognizable phrases, including medication information for Strensiq (asfotase alfa) Injection. However, much of the information is not readable.*

FDA Label Image

Principal Display Panel (18 mg/0.45 mL Vial Carton)

FDA Label Image

Principal Display Panel (28 mg/0.7 mL Vial Carton)

This appears to be a partially garbled text document with numerous errors and seems to be a combination of random characters, numbers, and letters with no clear context or coherent meaning. Thus, it is not available for evaluation.*

FDA Label Image

Principal Display Panel (40 mg/mL Vial Carton)

This appears to be a combination of several unrelated texts, including some errors and gibberish. The first part is not readable and may contain some non-English characters. The second part provides important information about a medication called Strensia, which is an injection containing asfotase alfa, used for subcutaneous administration in patients who weigh 40 kg or more. The medication comes in cartons that contain 12 single-use vials of 80 mg/0.8 mL and should be refrigerated. Any unused portion of the medication should be discarded, and it should not be mixed or diluted with any other solutions.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.